The registHER study, a prospective observational study of over 1000 HER2-positive metastatic BC patients, showed that the MOS after the diagnosis of CNS metastases was improved from 3.8 to 17.5 months with the administration of trastuzumab [12]. This evidence concerns the gene ERBB2 and breast cancer.